- Home
- TSLX vs RCKT Comparison
TSLX vs RCKT Comparison
Compare TSLX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSLX | RCKT |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 340.9M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | TSLX | RCKT |
|---|---|---|
| Price | $21.55 | $3.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 14 |
| Target Price | $23.50 | ★ $29.12 |
| AVG Volume (30 Days) | 449.1K | ★ 2.0M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 9.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $464,512,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.57 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.58 | $2.19 |
| 52 Week High | $25.17 | $13.35 |
Technical Indicators
Market Signals| Indicator | TSLX | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 42.35 | 46.08 |
| Support Level | $21.62 | $3.30 |
| Resistance Level | $22.00 | $3.57 |
| Average True Range (ATR) | 0.29 | 0.18 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 3.01 | 22.81 |
Price Performance
Historical ComparisonAbout TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.